Sugi Predict

Sugi Predict / Compounds / SCHEMBL834902

SCHEMBL834902

SCHEMBL834902

CC(C)COc1ccc(C(=O)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 3/20 0.70
▸ MAPK1 P28482 1/20 0.69
▸ RARB P10826 1/20 0.59
▸ POLB P06746 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ HPGD P15428 1/20 0.58
▸ XBP1 P17861 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ RXRA P19793 1/20 0.57
▸ RXRB P28702 1/20 0.57
▸ PLA2G4B P0C869 2/20 0.56
▸ PKM P14618 1/20 0.56
▸ SRD5A2 P31213 1/20 0.55
▸ TP53 P04637 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ NR4A1 P22736 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8652183 0.87 LMNA (0.63) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL27911613 0.86 FOS (0.61) NR1H4MAPK1POLBMAPTHPGD
SCHEMBL16109076 0.86 MAPT (0.56) NR1H4MAPK1POLBMAPTHPGD
SCHEMBL5151823 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL1304301 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL8544888 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL5151818 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL8544883 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL8730131 0.85 MAPK1 (0.60) NR1H4MAPK1RARBPOLBMAPT
SCHEMBL3010302 0.85 MAPT (0.73) NR1H4POLBMAPTHPGDXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 — — WO claimed
CN-110156664-B Method for synthesizing pimavanserin 常州大学 2022-03-01 — — CN claimed
CN-110156664-A A kind of synthetic method of piperazine Ma Selin 常州大学 2019-08-23 — — CN claimed
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 — — WO disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 — — US disclosed
CN-110156664-B Method for synthesizing pimavanserin 常州大学 2022-03-01 — — CN disclosed
CN-106588753-B Pimanerin preparation method 重庆医药工业研究院有限责任公司 2021-07-09 — — CN disclosed
CN-111825601-A Method for continuously preparing pimavanserin by using microchannel reactor 杭州珠联医药科技有限公司 2020-10-27 — — CN disclosed
US-10730865-B2 Compounds for modulating aquaporins APOGLYX AB (SE) 2020-08-04 — — US disclosed
US-10730865-B2 Compounds for modulating aquaporins APOGLYX AB (SE) 2020-08-04 — — US disclosed
CN-110156664-A A kind of synthetic method of piperazine Ma Selin 常州大学 2019-08-23 — — CN disclosed
CN-1774418-A Substituted N-arylheterocycles, method for production and use thereof as medicaments AVENTIS PHARMA GMBH (DE) 2006-05-17 — — CN disclosed
WO-2006018280-A2 ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-02-23 — — WO disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 — — US disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 — — EP disclosed
US-6001880-A DISUBSTITUTED N-(2-DIALKYLAMINOETHYL)BENZAMIDE DERIVATIVES OF GIVEN FORMULA; ANTIBACTERIAL ACTIVITY AGAINST HELICOBACTER PYROLI, ADMINISTERING FOR THE PREVENTION OR CURE OF PEPTIC ULCERS SHISEIDO CO., LTD. (JP) 1999-12-14 — — US disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 — — US disclosed
EP-0875501-A2 Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug SHISEIDO COMPANY LIMITED (JP) 1998-11-04 — — EP disclosed
WO-1998043649-A2 AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-10-08 — — WO disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730865-B2 Compounds for modulating aquaporins AQP1, AQP4, AQP3 NR1H4 751/4885MAPK1 1659/4885RARB 1986/4885
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 NR1H4 269/4885MAPK1 496/4885RARB 1841/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS NR1H4 2049/4885MAPK1 3349/4885RARB 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.